Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

ClinicalTrials.gov ID: NCT02571998

Public ClinicalTrials.gov record NCT02571998. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Multicenter Study to Evaluate the Safety and Efficacy of CLS001 Topical Gel Versus Vehicle Applied Once Daily for 12 Weeks to Female Subjects With Moderate to Severe Acne Vulgaris

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the safety and efficacy of Omiganan (CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in female subjects with moderate to severe inflammatory acne vulgaris.

Study identification

NCT ID
NCT02571998
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Maruho Co., Ltd.
Industry
Enrollment
320 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2015
Primary completion
Jul 31, 2016
Completion
Jul 31, 2016
Last update posted
Mar 26, 2017

2015 – 2016

United States locations

U.S. sites
29
U.S. states
17
U.S. cities
29
Facility City State ZIP Site status
Not listed Mobile Alabama
Not listed Phoenix Arizona
Not listed Santa Ana California
Not listed Santa Monica California
Not listed Denver Colorado
Not listed Boca Raton Florida
Not listed Boynton Beach Florida
Not listed Miami Florida
Not listed Pinellas Park Florida
Not listed Sanford Florida
Not listed Tampa Florida
Not listed Beverly Massachusetts
Not listed Fort Gratiot Michigan
Not listed St Louis Missouri
Not listed Las Vegas Nevada
Not listed Newington New Hampshire
Not listed Albuquerque New Mexico
Not listed New York New York
Not listed Stony Brook New York
Not listed High Point North Carolina
Not listed Raleigh North Carolina
Not listed Knoxville Tennessee
Not listed Arlington Texas
Not listed Austin Texas
Not listed Pflugerville Texas
Not listed San Antonio Texas
Not listed Webster Texas
Not listed Salt Lake City Utah
Not listed Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02571998, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 26, 2017 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02571998 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →